Document Detail

Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
MedLine Citation:
PMID:  24096615     Owner:  NLM     Status:  Publisher    
Bleeding risk (often perceived, rather than actual) is a common reason for cessation of oral anticoagulation with Vitamin K antagonists (VKA). We investigate clinical outcomes in a consecutive population of VKA naïve atrial fibrillation (AF) patients, who initiated VKA therapy in our clinic. We included consecutive VKA-naïve patients with non valvular AF, initiated on VKA therapy in our anticoagulation outpatient clinic in 2009. During follow-up, adverse events [thrombotic/vascular events (stroke, acute coronary syndrome, acute heart failure and cardiac death), major bleeding and death], and VKA cessation were recorded. At the end of the follow-up, we determined time within therapeutic range (TTR), using a linear approximation (Rosendaal method). We studied 529 patients (49% male, median age 76), median follow-up 835 days (IQR 719-954). During this period 114 patients stopped VKA treatment. 63 patients suffered a thrombotic/cardiovascular event (5.17%/year, 27 thrombotic/ischaemic strokes), 51 major bleeding (4.19%/year) and 48 died (3.94%/year). Median TTR was 54% (34-57). On multivariate analysis (adjusted by CHA2DS2-VASc score), VKA cessation was associated with death [Hazard Ratio (HR) 3.43; p<0.001], stroke [4.21; p=0.001] and thrombotic/cardiovascular events [2.72; p<0.001]. Independent risk factors for major bleeding were age [1.08; p<0.001], previous stroke [1.85; p=0.049], and TTR [0.97; p=0.001], but not VKA cessation. In conclusion, in AF patients AF, VKA cessation is independently associated with mortality stroke and cardiovascular events. Specifically, VKA cessation independently increased the risk of stroke, even after adjusting for CHA2DS2-VASc score. TTR was an independent risk factor for major bleeding following initiation of VKA therapy.
P Gallego; V Roldan; F Marín; M Romera; M Valdés; V Vicente; G Y H Lip
Related Documents :
23794465 - Prednisone in copd exacerbation requiring ventilatory support: an open-label randomised...
23512095 - The 'echo heart failure score': an echocardiographic risk prediction score of mortality...
23482995 - Evaluation of the in vivo efficiency and safety of hepatic radiofrequency ablation usin...
20678805 - Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment ...
19653405 - Progesterone effects on experimental tooth movement in rabbits.
18713185 - Long-term outcome after placement of a percutaneous endoscopic gastrostomy tube.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-10-07
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  110     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-10-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Prof. G. Y. H. Lip, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK, Tel.: +44 121 5075080, Fax +44 121 554 4083, E-mail:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The first one-pot synthesis of a chiral pentakis-adduct of C60 utilising an opened-structure malonat...
Next Document:  Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipin...